[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332824-105":3,"detail-sidebar-cat-0-en-105":84,"doc-detail-332824-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":77,"head_meta":79,"extra_data":81,"updated_unix":83},105,"en","clinicopathological-features-and-prognostic-significance-of-taf1l-in-gastric-cancer-research-article-summary","Clinicopathological features and prognostic significance of TAF1L in gastric cancer - Research Article Summary","","TAF1L is proposed to influence gastric cancer development, yet its relationship with clinicopathological factors and patient prognosis remains unclear. A cohort of 120 eligible gastric cancer patients was evaluated using immunohistochemistry for TAF1L expression, with additional bioinformatics support from the TCGA GC dataset. Higher TAF1L levels correlated with worse outcomes, including independent prognostic value in multivariate Cox models and associations with HER2, dMMR, and pMMR contexts. The study suggests TAF1L as a prognostic biomarker with potential therapeutic relevance.",{"@graph":14,"@context":76},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinicopathological-features-and-prognostic-significance-of-taf1l-in-gastric-cancer-research-article-summary/332824/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinicopathological-features-and-prognostic-significance-of-taf1l-in-gastric-cancer-research-article-summary/332824.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68,72],{"name":59,"@type":60,"acceptedAnswer":61},"What was the study goal regarding TAF1L in gastric cancer?","Question",{"text":62,"@type":63},"To determine whether TAF1L expression is associated with clinicopathological features and prognosis in gastric cancer, and to assess its value as a potential biomarker.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How was TAF1L expression measured in the patient cohort?",{"text":67,"@type":63},"TAF1L expression in 120 clinical gastric cancer samples was detected using immunohistochemistry, and correlations with prognosis were analyzed.",{"name":69,"@type":60,"acceptedAnswer":70},"What clinical features were associated with higher TAF1L expression?",{"text":71,"@type":63},"Higher TAF1L expression was associated with tumor differentiation, signet-ring cells, dMMR status, lympho-vascular invasion, and neural invasion.",{"name":73,"@type":60,"acceptedAnswer":74},"Is TAF1L an independent prognostic factor?",{"text":75,"@type":63},"Yes. Multivariate Cox regression indicated TAF1L as an independent prognosis factor, and subgroup analyses showed independent prognostic risk in specific HER2-positive and pMMR groups.","https://schema.org",{"og:url":32,"og:type":78,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":80,"canonical":32},"index,follow",{"doc_id":82,"site_id":7},332824,1792169249,{"code":4,"msg":85,"data":86},"success",[87,91,95,99,104,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},"Exam",70,"exam",{"id":100,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},5,"Comic",60,"comic",{"id":105,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},6,"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":100,"slug":133},19,"General","general",{"code":4,"msg":85,"data":135},{"doc_id":82,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Chen et al. BMCGastroenterology (2024) 24:445 [https://doi.org/10.1186/s12876-024-03534-y](https://doi.org/10.1186/s12876-024-03534-y)  \nBMC Gastroenterology  \nRESEARCH Open Access  \nClinicopathological features and prognostic significance ofTAF1L in gastric cancer  \nHan Chen 1,3†, Hang Chen 1,3†, Jingquan Fang 1†, Xingmao Huang 1, Xiu Zhu2, Tengjiao Chai 1, Xiangliu Chen 1, Ling Huang 1 and Pengfei Yu 1*  \nAbstract  \nBackground TAF1L may play an important role in the occurrence and development of gastric cancer (GC), but the correlation between the expression ofTAF1L and the clinicopathological factors and prognosis of GC is still unclear. Methods A total of 1053 GC patients in Zhejiang Cancer Hospital between January 1st, 2018 to December  \n31th, 2019 were screened. Finally, 120 patients met the inclusion criteria. TAF1L expression was detected by immunohistochemistry, and the correlations ofTAF1L in clinicopathological characteristics and prognosis were analyzed. TCGA GC dataset was used to perform further bioinformatics analysis.  \nResults In this study, TAF1L expression was evaluated in 120 clinical samples of GC. TAF1L expression was higher in tumor tissues and was associated with tumor differentiation (p = 0 . 046), signet-ring cells (p = 0 . 043), dMMR  \nstatus (p = 0 . 011), lympho-vascular invasion (p = 0 . 038), and neural invasion (p = 0 . 005) in our cohort. Cases with high expression ofTAF1L presented worse mean OS than those with low expression (40 .3 months vs. 51.8 months, p = 0 . 019), and the difference was also significant in HER2-positive cases (20 .9 months vs. 51.2 months, p = 0 . 007) as well as pMMR cases (38 . 8 months vs. 51.6 months, p = 0 . 006) . Multivariate Cox regression analysis showed that TAF1L (HR = 2 . 044, 95%CI = 1 .007–4. 147, p = 0 . 048) and HER2 status (HR = 2 . 383, 95%CI = 1 .087–5. 222, p = 0 . 030) were independent prognosis factors of these patients. In subgroup analysis, TAF1L was the independent prognostic  \nrisk factor in HER2-positive patients (HR = 6 . 736, 95%CI = 1 .373–33. 032, p = 0 . 019) . and pMMR patients (HR = 2 . 291, 95%CI = 1 .126–4. 660, p = 0 . 022) . Besides, HER2 status was the independent prognostic risk factor inTAF1L-H patients (HR = 4 . 832, 95%CI = 1 .908–12. 239, p = 0 . 001) . TCGA dataset also indicated the higher expression ofTAF1L in tumors than normal tissues (p \u003C 0. 001) . HighTAF1L expression is linked to worse survival in MSS (11 .0 months vs. 35.0 months, p = 0 . 0046) groups, and is negatively associated with overall survival in HER2-positive cases (24 .0 months vs. 57.0 months, p = 0 . 0039) .  \nConclusion TAF1L is closely related to the occurrence and development of GC. Our results suggested thatTAF1L is a significant biomarker for predicting prognosis of GC and may play an important role in immunotherapy and targeted therapy.  \n†Han Chen, Hang Chen and Jingquan Fang contributed equally to this work.  \n*Correspondence: Pengfei Yu [ypfzmu@163.com](ypfzmu@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission di","cbCaiihHtCqdzSK4","https://ap.wps.com/l/cbCaiihHtCqdzSK4","pdf",2038617,11,"English","# Abstract\n# Introduction\n# Materials and methods\n## Patient inclusion\n# Results\n# Conclusion","[{\"question\":\"What was the study goal regarding TAF1L in gastric cancer?\",\"answer\":\"To determine whether TAF1L expression is associated with clinicopathological features and prognosis in gastric cancer, and to assess its value as a potential biomarker.\"},{\"question\":\"How was TAF1L expression measured in the patient cohort?\",\"answer\":\"TAF1L expression in 120 clinical gastric cancer samples was detected using immunohistochemistry, and correlations with prognosis were analyzed.\"},{\"question\":\"What clinical features were associated with higher TAF1L expression?\",\"answer\":\"Higher TAF1L expression was associated with tumor differentiation, signet-ring cells, dMMR status, lympho-vascular invasion, and neural invasion.\"},{\"question\":\"Is TAF1L an independent prognostic factor?\",\"answer\":\"Yes. Multivariate Cox regression indicated TAF1L as an independent prognosis factor, and subgroup analyses showed independent prognostic risk in specific HER2-positive and pMMR groups.\"}]","Clinicopathological features and prognostic significance of TAF1L in gastric cancer - Research Article Summary | PDF",1789999638,28]